Cell Suppression Theory: A Meta-Model That Challenges the Standard Cancer Narrative

In Part 1 of our 3-part series, Mark Lintern (author of The Cancer Resolution?) challenges the conventional “somatic mutation theory” of cancer and introduces his “cell suppression” framework—a meta-model that attempts to explain why cancer behaves so consistently despite highly variable mutations.

We explore:

• Why “random mutations” struggle to explain consistent cancer hallmarks
• Cancers with no clear driver mutations
• The Warburg effect (glycolysis) and a different interpretation via the “cell danger response”
• Why metabolic + immune biology may be central to the cancer story
• What it could mean if tumors function like biological ecosystems

📌 Disclaimer: Educational content only. Not medical advice.

Listen to here or watch the full episode on YouTube here: https://youtu.be/1O13BXPnWEA

Visit UltraBotanica.com to learn more about us and how you can get a free sample of our products.

Transcript

0:00:00 - (Mark Lintern): If we use an analogy of playing a piano, so playing certain keys in a certain sequence on a piano plays a really nice tune. What a somatic mutation theory is kind of suggesting is that it doesn't matter what keys you play, you will still get the same tune. Doesn't matter what mutations occur, you're still going to get the same growth in the same. Exactly the same manner, following the same path. Well, it's very difficult to explain how utter randomness can cause that consistency.

0:00:25 - (Mark Lintern): But it's not just that, because we find that there's a number of cancers now that develop without any driver mutations at all. So bare minimum in those cancers, something else is driving it.

0:00:49 - (Adam Payne): Welcome to ultra life today. Today we have an amazing guest, Mark lintern. You know, for decades, cancer has been understood primarily as a genetic and cellular malfunction, A story of mutations, signaling errors, and metabolic breakdown. That framework has produced real progress, but it has also left important questions unanswered. Modern tumor sequencing generates far more information than just human DNA.

0:01:14 - (Adam Payne): For years, much of that additional genetic material was ignored. But in 2022, researchers went back and asked a simple but profound question. What else is living inside of tumors? What they found was fungal DNA, not randomly, not occasionally, but in structured patterns that varied by cancer type and repeated across countries and laboratories. This discovery doesn't just discard everything that we know about cancer, it expands it.

0:01:44 - (Adam Payne): Our guest today is Mark lintern, author of the cancer resolution. Mark brings together these findings with metabolic theory and immune biology into a unified way of understanding cancer, not as a simple accident of broken cells, but as a living biological ecosystem. Today's conversation is about this new perspective and what it reveals and how it may reshape the future of cancer care. Mark, welcome to the show. How are you doing today?

0:02:15 - (Mark Lintern): I'm doing fantastic. Thank you. Thank you for having me on the show. It's a pleasure to be here.

0:02:20 - (Adam Payne): So this conversation today, we really want to dive into kind of this unified model that you've developed. And for listeners that are new to your work, how would you describe cell suppression theory in clear, everyday language?

0:02:35 - (Mark Lintern): It could be seen as a meta theory that explains a number of key parts of the cancer puzzle that still remain unexplained, but it sits as an adjunct to the other. The are currently available and highlights these areas to show how all these different theories fit together and where all these other parts of the disease that remain unexplained can be explained through this process.

0:03:03 - (Adam Payne): I have both me also in the studio, my dear friend Kyle. Drew. Kyle, you were A part of a whole ecosystem with Know the Cause by Doug Kaufman.

0:03:14 - (Kyle Drew): Yeah, Doug Kaufman, author of the Fungus Link series of books and host of Know the Cause. And Mark, when I began reading your work some time ago, I was enamored and I was heartened. And again, I, I think that so much of what you've brought together represents a huge missing piece of the puzzle. But it's not just one piece, Mark. And this is one of the things I wanted to ask you. You talk in your book the Cancer Resolution about the hallmarks of cancer. The 10 agreed upon hallmarks of cancer of them might be something like uncontrolled growth or immune evasion.

0:03:58 - (Kyle Drew): And the dominant theory of cancer is the so called somatic mutation theory. Exactly. And while that's the dominant theory, it really only hits a couple of those hallmarks. Would you mind talking about that a little bit? And how the cell suppression theory that you've developed helps to bridge the gap between just the small number of hallmarks versus the.

0:04:25 - (Adam Payne): At its core, though, I just want to say this. The somatic theory has failed. Not just because it's. I don't think it's not a great theory, but all that pharmaceutical science has tried to build as an answer to the somatic defect theory has failed. All of these gene interventions going in that should essentially answer the defect that's going on in cancer. The efficacy less than 2% for most of these interventions.

0:04:56 - (Kyle Drew): Yeah, and I'm going to mention something about that. But Mark, talk about the hallmarks of cancer and why somatic theory fails so much for you.

0:05:04 - (Adam Payne): Why does it fail?

0:05:06 - (Mark Lintern): Well, I can understand why science has gone down that route. You know, from the 1950s. There's only so much we know at any given moment in time. And it was an exciting time when they understood the structure of DNA. And it's thought to be kind of like the God particle really, isn't it? The God.

0:05:21 - (Adam Payne): Yeah.

0:05:22 - (Mark Lintern): Part of the cell you can create. If you can manipulate and understand the DNA, you can create whatever you want or solve any particular disease in that sense. But since then it's been shown that actually probably about 1.2, 1.3% of mutations actually relate to any particular disease in general. That was John Initis, his paper, I forget the date of that paper, but he did an extensive study on that to show that, you know, DNA mutations aren't exactly the direct cause of most disease. In fact, they may add to those diseases.

0:05:56 - (Mark Lintern): But throughout the decades, I can see why so much investment went into trying to understand this very complex mechanism behind Essentially the blueprint of the cell. But we know it's. It's not so much that anymore, because there's a lot of epigenetics that affect everything that's going on. Um, we get into the future, everyone's assuming that this is the underlying mechanism behind the disease. We have lots of investments. So you've essentially got this big juggernaut now going full steam ahead, Trying to understand the genetics of cancer.

0:06:25 - (Mark Lintern): Uh, the human genome project came out that took about 15 years to literally catalog all the DNA genes. So still, we, We. We didn't really have enough information. Um, we weren't able to catalog everything that was going on in. In the cell at any given moment in time. And sure, there were mutations happening. See why people kind of. Still. Scientists still believed that this was one of the main mechanisms driving cancer. But it wasn't until the cancer genome atlas project, which started around 2003, 2005, where technology had improved so much, that they could now catalog the DNA mutations occurring in. In a broad number of cancers In a relatively short period of time. Rather than 15 years, it would.

0:07:12 - (Mark Lintern): Was taken six months, a year or so. But when they did release that data, they began to realize that the data wasn't showing the kind of results that they were expecting. So they're expecting sequential mutations, Like a pattern of mutations that you would have with skin cancer or whatever cancer type. Type of cancer it was. And that would be the same for everyone who had that particular type of skin cancer. It would be a pattern. We could target those specific mutations with drugs.

0:07:44 - (Mark Lintern): However, in 2013, when a lot of the evidence came about and it was analyzed, A lot of the mutation. Well, most of the mutations were random, utterly random. And it didn't really make any sense at that point. So the key point I would highlight here is the reason why it doesn't make much sense is because those 10 hallmarks you were talking about, Kyle, they represent the consistency of the disease. So here we have a prospect where you've got utter randomness. And we're not just talking randomness from one cancer to the next. We're talking about randomness of mutations within different cells of the same tumor.

0:08:20 - (Kyle Drew): Right?

0:08:21 - (Adam Payne): Yeah. So it wasn't. There were. There weren't. It wasn't a consistent effect that they were seeing in any. In any particular cancer cell.

0:08:30 - (Mark Lintern): And it wasn't just the randomness. But if you. If you think about this on the level of, like, if we use an analogy of playing a piano, so playing certain keys in a certain sequence on a piano plays A really nice tune. What a somatic mutation theory is kind of suggesting is that it doesn't matter what keys you play, you will still get the same tune. Doesn't matter what mutations occur, you're still going to get the same growth in the same, exactly the same manner, following the same path.

0:08:55 - (Mark Lintern): Well, it's very difficult to explain how utter randomness can cause that consistency. But it's not just that, because we find that there's a number of cancers now that develop without any driver mutations at all. So bare minimum in those cancers, something else is driving it. Even if it would be genetic mutations driving the other forms of the disease, or you still speculate that could be the case, you now have a set of cancers that need to be explained by another mechanism.

0:09:27 - (Mark Lintern): And that should open the doors to a lot more research into trying to find out what that other mechanism can be. But it seems to have been sidelined. And then if you go down that route and you actually do find that other mechanism, you could then argue, well, how do we apply that mechanism to the other, other cancers that have got mutations? Because it might apply to them as well. But it just seems like no one's really taken the time to go down that route and look at these other cancers that don't have any mutations. But then there's recent studies that have shown that the average mutation rate is about 1.7 mutations per cell.

0:10:03 - (Mark Lintern): And you know, there aren't enough mutations essentially to drive the disease under this somatic mutation model. And then there's mutations in healthy tissue that you don't get cancer developing. Then you have the DNA transfer experiments where they essentially took the nucleus taken from tumor cells, tumors, and they replaced, place that into healthy tissue, healthy cells, and they expected to see abnormal growth. Because that's what you would expect to see, right?

0:10:27 - (Adam Payne): Yeah. You take, you take the DNA from a cancer cell, put it into a healthy cytoplasm. This is what Seyfried did in his whole group with the metabolic approach to cancer.

0:10:38 - (Mark Lintern): He did, he did.

0:10:40 - (Adam Payne): And what happens is exactly the opposite. Right. So the cancer nucleus in the healthy cytoplasm, guess what, stays healthy. And you take a healthy nucleus, put it into the cancer cytoplasm, and it turns cancerous. So, wah, wah. Somatic mutation theory gets thrown out the wall door.

0:11:00 - (Kyle Drew): Well, and, and Mark, one of the things, and I just want to point this out for folks on your website, cellsuppression.com you have this wonderful synopsis paper, the cell suppression theory synopsis. I hope everybody goes to your website and Looks at this and then gets a copy of your book. One of the things you were just talking about this.

0:11:23 - (Adam Payne): And where can the book. It's cell suppression theory. The.

0:11:26 - (Kyle Drew): Yeah, cell suppression dot com. And then I got mine on Amazon. Mark. Yeah, it's my copy of the book. And you're talking in this synopsis about the shortcomings of the dominant theory. And then you switched over to talking about the five year survival rates, the average five year survival of various cancers. And you start listing them out. Liver cancer, 5 year survival when you are at stage 4, 5% pancreatic, 3%, stomach, 6%. The greatest, the highest one, the highest 5 year survival at stage 4 is non Hodgkin's lymphoma at about 30%.

0:12:11 - (Kyle Drew): In other words, by funneling so many resources into the somatic mutation theory, the results are often single digit survival rates at the five year mark at a certain stage of growth.

0:12:29 - (Adam Payne): Let's help our listeners here because some of them might be a little bit confused. Somatic theory of cancer is essentially the predominant theory which says that genes, defects in genes is what causes cancer. And so guys, that's when we say the somatic theory of cancer is proving invalid. We're saying that this whole theory about your genes getting damaged, causing cancer, let's just, let's throw that theory out with the bathwater because it's proven at its core not to be valid.

0:13:02 - (Adam Payne): Now, genes do play a role, but really what we're talking about is a new theory that Mark Lintern has put together in the cancer resolution. And let's get back to the question that you were asking there. Just want to make sure people understood because when we say somatic theory, we understand it right.

0:13:19 - (Kyle Drew): Genetic mutation being the central cause of cancer. That's what the theory states. And so thank you for summarizing that because Mark, when I was reading this, you really did a beautiful job of putting the horror story in black and white of well, how are we doing after, after kind of using this approach for 75 years? How we doing so far? Are we making progress? And Mark, to me, I, I'm not sure that the progress has been worth the investment.

0:13:54 - (Kyle Drew): But what are your thoughts?

0:13:57 - (Mark Lintern): Yeah, I agree. And that was one of the big issues with my research. It became clear quite early on when I started my research. I mean, I believed initially that cancer was a genetic disease because that's what we were all taught, right? So I was searching in the medical literature to find the mutations that caused my particular cancer when I was diagnosed. And it's only Then that you realize that it's not related to too much that is out there. You can't. There's no pattern.

0:14:25 - (Kyle Drew): You mention your own diagnosis. I am assuming that this is what fueled your interest in really going deep and staying down long, coming back to the surface with more answers than questions. So maybe talk a little bit about your own story and what has fueled this research.

0:14:47 - (Mark Lintern): Yeah, so I developed cancer when I was 28. It was just a skin cancer, essentially. So I was lucky. I managed to get it removed via surgery. But that threw me into researching the disease basically. And it was quite quickly after that, after about three months, three, four months of doing research, I came across these other theories and a number of issues. I had already surfaced with the genetic theory, the randomness that I saw in the research.

0:15:18 - (Mark Lintern): And then I stopped after I'd been given the all clear, essentially. A couple of years later, a good friend of mine, Sam, she developed cervical cancer at the age of 30. So I began my research again and that lasted a year. I did a year's deep dive because after the year, unfortunately, she passed away.

0:15:36 - (Adam Payne): Oh my goodness.

0:15:38 - (Mark Lintern): In that process, I was trying to point of the research was to help her as much as I could to provide other potential adjuvants she could use to try and help her through chemotherapy and various other things to improve her survival. But unfortunately, she went down to the mainstream treatment route, standard of care, and within like say a year, she passed away. So that led that, that provided me with the motivation, really.

0:16:04 - (Mark Lintern): I didn't want to go through that process again. I didn't want anyone else to. Any of my loved ones to experience that. So I thought, I've understood quite a bit about the biology of human biology and cancer biology. I'll put what I know down in a little pamphlet or something so that if anyone I know gets cancer again, I can provide them with that. And that would set them on a path of interest, looking at other things, not just going along with standard of care. Not saying that standard of care can't help, it can in some cases.

0:16:33 - (Mark Lintern): But this would help anyone who developed the disease on my side. And then of course, because I'd learned so much, I didn't want to give this away. I was motivated, I was angry. Because of Sam's death, I could already see things that weren't. That were going wrong. I mean, she was being given Avastin three months before she was. She passed away. And I'd already researched Avastin and realized that it had been taken off the market previously for breast cancer. Because it showed no long term benefit at all.

0:17:02 - (Mark Lintern): So that motivated me. I carried on going. I then came across the metabolic theory and a number of other theories. But for me it became clear that metabolic theory was one of the leading established theories. And then one thing led to another. I was writing a book at this point. It wasn't just a pamphlet, it was a book. But then I came across a couple of contentions with the metabolic theory itself that led me on to some further research.

0:17:30 - (Mark Lintern): I wasn't even looking at cancer at this point. I was looking at infection based models. And something struck me. In that paper, they described the Warburg effect. In that paper, nothing related to cancer, but they were talking about how infection triggers the Warburg effects. Now, the Warburg effect is what the metabolic theory describes as the underlying mechanism that drives cancer. And that is when the energy system switches from, you could say the primary energy system or the, yeah, the primary energy system to the backup energy system of glycolysis.

0:18:01 - (Mark Lintern): So cancers favor that process. And that's been termed the Warburg effect because Otto Warburg discovered this shift in energy that's abnormal for cancers. But I've basically come up with a completely different explanation for why the Warburg effect could be occurring in cancer. And it's all related to infection.

0:18:22 - (Kyle Drew): And when you discovered this, I'm sure that you were thinking, oh, gosh, this is kind of outside the mainstream. But what I think in my mind, what helps is the work of, for example, Thomas Seyfried and the metabolic theory. I know that this is not contending with metabolic theory. It's working in conjunction with metabolic theory to give a more rounded, full approach to the concept of how do we get cancer and by extension, how should we be treating cancer? Am I going kind of balanced with that?

0:19:00 - (Adam Payne): So this is pointing to the question, what is fungus doing in our bodies that's causing this cancer? So you made the link that fungus infections can cause cells to have the Warburg effect being expressed, but what is going on to bring it from a cell having the Warburg effect? How is fungus causing the cell to turn into a cancer phenotype?

0:19:31 - (Mark Lintern): So it will be best to explain this through Dr. Navier's cell danger response model. Yeah, he describes. So if we describe cancer first through the metabolic theory, the notion there is, you have these two synergistic energy pathways. There's more energy pathways than that, but these are the main two. So let's call it OXFOs, goes through mitochondria. That's where glucose and oxygen is converted. Ess into energy in the mitochondria, which are the organelles which resemble bacteria.

0:20:02 - (Adam Payne): And it's a very efficient system. One glucose makes I think 42 ATP, which is incredible.

0:20:10 - (Mark Lintern): Yeah, it is one glucose molecule. But the issue of that is that oxygen is required to produce energy. So if you have an event where you have damage to the cell and you have hypoxia, loss of oxygen, the cell needs to be have a backup energy system in order to survive essentially for a short period of time until the blood vessels. Yeah. So they do, they have this backup energy system called glycolysis. I mean there's two parts to that, but won't really go into detail. But just to keep it simple, glycolysis that produces lactic acid. And what lactic acid does is it actually stimulates blood vessel growth. So there's a switch over to lactic acid to gluc glycolysis, which is where the cell ferments glucose so it doesn't need oxygen.

0:20:54 - (Mark Lintern): So that's beneficial obviously for when you lose the oxygen supply. Now that produces around two ATP units of energy for every glucose molecule. So you need at least 18 times, 20 times glucose molecules to provide the same energy output that you would do through mitochondrial oxygen.

0:21:11 - (Adam Payne): Yeah, it's extremely less efficient. But yes, it's the backup. Right.

0:21:16 - (Mark Lintern): So it's absolutely, it's not really designed to be on for a prolonged period of time.

0:21:21 - (Adam Payne): Right.

0:21:22 - (Mark Lintern): So that's the difference, that's what happens with cancer and it's known as the Wahlberg effect because what we see in cancer is that oxygen is still being absorbed into the cell. So if oxygen is still being absorbed into the cell, technically mitochondria should still be using that oxygen to produce energy. The fact that we've got this switch to glycolysis, the backup energy system, even in the presence of oxygen, suggested to Otto Warburg that the mitochondria must be damaged. So it's forcing this switch.

0:21:51 - (Mark Lintern): Now that's the basic premise. The OXFOS pathway in mitochondria are dysfunctional to a certain degree that they it no longer produces sufficient energy, ATP energy for the cell to survive. So it is forced to switch over to this backup energy system, corrosive lactic acid producing energy system. Now the difference with my theory is that when a fungal pathogen is detected or invades the cell, and I'll go through this as Dr. Robert Navier explains it, because he created something called a cell danger response model.

0:22:24 - (Mark Lintern): And this model explains what happens when the cell experiences danger, a toxin, damage Pathogen, whatever it is, it goes through a three step process, CDR1, which is the initial process of alerting the immune system inflammation, switching over to glycolysis. And the whole process point of this is to eliminate the pathogen or the toxin. Stage two is where the signaling comes in more intensely regarding repairing the tissue. So you've got to assume that stage one has been going on for a short period of time as say, an acute inflammation. You damage the tissue, you eliminate the pathogen, it moves over to step two. You then need to repair the cell. So you're now drawing in a lot more nutrients so you can repair the cell and the tissue and then it moves on to stage three.

0:23:08 - (Mark Lintern): Step three, CDR three, which is essentially dampening down all these mechanisms for cell repair and the tissue returns back to homeostasis. Well, how Dr. Navier describes an infection in the CDR1 phase is that the pathogen is acknowledged by the cell and it's the mitochondria specifically that are monitoring everything going on. There's so much more than just an energy organelle. They actually the cell defense mechanism, they monitor many different aspects of cell functionality.

0:23:40 - (Mark Lintern): And one of them is when pathogens attack. When that happens, the mitochondria intentionally suppress oxfos. So they intentionally suppress the pathway that is thought to be damaged in the metabolic theory. So that suppression makes it appear as though mitochondria aren't working and forces a switch in energy to glycolysis. Because now that mitochondria aren't producing ATP, because what they're actually doing is they're taking that oxygen being absorbed into the cell to actually target the pathogen with reactive oxygen species.

0:24:16 - (Mark Lintern): Also, reactive oxygen species are used for cell signaling. So they're trying signaling for inflammation to alert the immune system to the issue. So they're repurposing the oxygen. That means that they're no longer creating ATP energy, but they're using it proactively to defend the cell that forces this switch to glycolysis. Because glycolysis is now providing the ATP that allows the mitochondria to do their other job of defending the cell.

0:24:42 - (Mark Lintern): So that's essentially the shift that occurs and that offers a new and novel narrative for the reason why the Warburg effect could be occurring in cancer. It's the fungal pathogen that's driving that process.

0:24:56 - (Adam Payne): Yeah, I think we're going to bring a close to this first segment here. And Kyle, do you want to just frame where we've been and how and where we got to here for the moment?

0:25:06 - (Kyle Drew): Well, when we are confronted with cancer, we are hit with one dominant theory when we go the conventional medicine route, and that is something called the somatic mutation theory, which just means that the DNA has mutated and it's done spontaneously. We don't know any particular reason why. And we have cancer. All of the treatments, most of the treatments that are available to us are reflective of that theory. But what if that theory is wrong?

0:25:41 - (Kyle Drew): What if there is another approach? And our guest today has been Mark Lintern, who's written the Cancer resolution. The cancer resolution. And there's a question mark behind that. I don't think that you need a question mark, Mark, but that's just me. But the. The cancer resolution. His website is cellsuppression.com cellsuppression.com the Cell Suppression theory is what Mark has developed. And I think that it's got some real steam behind it.

0:26:11 - (Adam Payne): It's got some bones to it.

0:26:13 - (Kyle Drew): It does. And I think, Mark, that you've done a tremendous work. And I'm looking forward to our next conversation. But thanks for being with us today, brother.

0:26:21 - (Adam Payne): Yeah, thanks for joining us today at Ultralife today. Please come back to us next week when we continue our discussion with Mark Lintern.